Digital Care Programs for Female Pelvic Health

Sponsor
Sword Health, SA (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05513417
Collaborator
(none)
50,000
1
124
403.1

Study Details

Study Description

Brief Summary

The purpose of this study is to create a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs.

This will allow the investigators to observe the acceptance, engagement and outcomes of programs using this approach in the treatment of multiple pelvic health disorders.

Condition or Disease Intervention/Treatment Phase
  • Device: Bloom Pod

Detailed Description

This patient registry was designed as a research repository, composed of data collected in the course of digital care programs for pelvic health conditions by SWORD Health/Bloom to individuals undergoing those programs.

This data will allow the researchers to:
  1. Assess the adoption, engagement and feasibility of digital care programs for pelvic musculoskeletal disorders and pelvic health;

  2. Assess the results of digital care programs and compare the costs with the benefits obtained;

  3. Correlate the results with patient's demographic and clinical profiles;

  4. Examine the impact of mental health and the behavioral modification components of Bloom's interventions on disease markers, comorbidities, and productivity;

  5. Increase the knowledge on several pelvic musculoskeletal disorders, namely how they progress and respond to digital care programs;

  6. Develop new or improved tools to assist clinicians in the management of these disorders and in helping people achieve better pelvic health

The primary outcome will be the evolution of the participant's condition along the program. Depending on the condition, primary and secondary outcome measures vary, but the registry will include, in all cases, a complete characterisation of the participant's pelvic health status, as well as the periodic assessment of: a) performance indicators (through condition-specific tests); b) patient-reported outcomes (obtained using internationally validated pathology-specific questionnaires); c) pain levels; d) compliance; e) patient satisfaction

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
50000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Digital Care Programs for Female Pelvic Health: a Large-scale, Multi-disorder, Observational Study
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2032
Anticipated Study Completion Date :
Dec 1, 2032

Arms and Interventions

Arm Intervention/Treatment
Intervention

These programs will cover participants with pelvic floor conditions which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these conditions.

Device: Bloom Pod
Pelvic floor program consisting of exercise performed while using the device, education and behavioural change

Outcome Measures

Primary Outcome Measures

  1. Self-reported symptom level [Baseline, and then at regular intervals (after 9, 15 and 30 sessions) after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time in clinical outcomes common to all conditions measured through a 0-10 Pain Numerical Rating Scale referring to the previous 7 days. Higher scores mean more symptoms.

  2. Pelvic Floor Impact Questionnaire - short form 7 (PFIQ-7) [Baseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    The PFIQ-7 consists of 7 questions that need to be answered 3 times each considering symptoms related to the bladder or urine, vagina or pelvis, and bowel or rectum and their effect on function, social health, and mental health in the past 3 months. The responses for each question range from "not at all" (0) to "quite a bit" (3). To get scale scores, the mean of each of the 3 scales is individually calculated, which ranges from 0-3, this number is then multiplied by 100 and then divided by 3. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.

Secondary Outcome Measures

  1. Anxiety [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through General Anxiety Disorder-7 (GAD-7) is a 7-item scale (scores 0-21). Higher scores mean higher anxiety levels.

  2. Depression [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through Patient Health Questionnaire-9 (PHQ-9), a 9-item scale (0-27). Higher scores mean higher depression levels.

  3. Work productivity and absenteeism [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through Work Productivity and Activity Impairment Questionnaire (WPAI) assessed by the sub-scores: WPAI overall (combining presenteeism and absenteeism), WPAI work (presenteeism), WPAI time (absenteeism) and WPAI activities (activities of daily living impairment) (scores 0-100%). Higher scores mean greater impairment.

  4. Self-reported consumption of painkillers [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through Self-reported consumption of painkillers (yes/no); Prescription drugs (yes/no); Opioids (yes/no)

  5. Self-reported intent to seek additional healthcare services [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through a numerical rating scale (0-100). Higher scores mean higher intent.

  6. Self-reported fatigue (VAS) [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through a 0-10 Visual Analogue Scale. Higher scores mean higher fatigue.

  7. Self-reported symptom level (VAS) [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    Change over time common to all conditions measured through a 0-10 Visual Analogue Scale. Higher scores mean more symptoms.

Other Outcome Measures

  1. Sessions performed [Measured at the end of the program, an average of 10 weeks]

    Number of total exercise sessions performed

  2. Self-reported satisfaction [aseline, then 3, 5 and 10 weeks after program initiation, and then at 6, 12 and 24 months after enrolment]

    measured through the Net Promoter Score question collected at end of program: "On a scale from 0 to 10, how likely are you to recommend SWORD's programs to a friend or family member?")

  3. Total treatment time [Measured at the end of the program, an average of 10 weeks]

    Number of minutes spent on exercise sessions (aggregated)

  4. Average treatment time per week [Measured at the end of the program, an average of 10 weeks]

    Average number of minutes spent on exercise per week

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Over 18 years old;

  • Signs/symptoms consistent with an acute (<12 weeks) or chronic (>12 weeks) abdominopelvic condition without signs/symptoms indicating underlying disease states that require immediate referral for medical management OR recovering from pelvic surgery with indication from their surgeon to engage in a pelvic physical therapy program

  • Able to understand study procedures and willing to provide informed consent.

Exclusion Criteria:
  • Health condition (cardiac, respiratory, neurological, immune) condition incompatible with at least 20 minutes of light to moderate exercise if not cleared by a physician to engage in an exercise program

  • Bone fractures or other musculoskeletal conditions in which mobilization of the segment or joint is contra-indicated

  • Rapidly progressive and new in onset neurological complaints if not cleared by a physician to engage in an exercise program; or signs of acute, serious neurologic compromise

  • Active cancer diagnosis or receiving treatment for cancer if not cleared by a physician to engage in an exercise program

  • Signs/symptoms consistent with inflammatory bowel diseases (Crohn's, ulcerative colitis, etc.)

  • Signs/symptoms consistent with an active pelvic infection

  • Aphasia, dementia or any other psychiatric comorbidity that interferes with the use of the medical device

  • Complicated or high-risk pregnancy

  • Hemodynamic instability

  • Significant trauma to the area of pain within the last 12 weeks and functional incapacity and not cleared by a physician to engage in an exercise program

  • Surgery within the last 12 weeks and not cleared by a physician to engage in an exercise program

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sword Health Inc Draper Utah United States 84020

Sponsors and Collaborators

  • Sword Health, SA

Investigators

  • Principal Investigator: Fernando Correia, PhD, Sword Health, Inc

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sword Health, SA
ClinicalTrials.gov Identifier:
NCT05513417
Other Study ID Numbers:
  • BL-OBS-PH-US-01
First Posted:
Aug 24, 2022
Last Update Posted:
Aug 24, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2022